

Russell 1000 Health Care RIC 22.5/45 Capped Index

Data as at: 31 July 2024

The Russell 1000 ICB Capped indexes are US large cap sector indexes based on the Russell 1000 Index and Industries within the ICB sector classification framework. The indexes apply regulatory capping targets at the quarterly reviews, in consideration of either the Regulated Investment Company (RIC) requirements for diversification or the definition of a “Diversified Company” via SEC.5.b(1) of the Investment Company Act of 1940 (40 Act). The 40 Act Daily Capped indexes are monitored daily, and the methodology is designed to maintain constituent weights below 40 Act thresholds.

The Russell 1000 Health Care RIC 22.5/45 Capped Index measures the performance of US large cap companies that are assigned to the Health Care Industry by the ICB sector classification framework. At the quarterly index reviews, all companies that have a weight greater than 4.5% in aggregate are no more than 45% of the index, and no individual company in the index has a weight greater than 22.5% of the index.

10-Year Performance - Total Return



— Russell 1000 Health Care RIC 22.5/45 Capped Index

Performance and Volatility - Total Return

| Index (USD) | Return % | | | | | Return pa %* | | Volatility %** | | | |
|---|----------|-----|------|------|------|--------------|-----|----------------|------|------|------|
| | 3M | 6M | YTD | 12M | 3YR | 5YR | 3YR | 5YR | 1YR | 3YR | 5YR |
| Russell 1000 Health Care RIC 22.5/45 Capped Index | 7.1 | 7.6 | 10.6 | 13.0 | 14.9 | 76.3 | 4.7 | 12.0 | 10.5 | 15.2 | 14.8 |

* Compound annual returns measured over 3 and 5 years respectively

** Volatility – 1YR based on 12 months daily data. 3YR based on weekly data (Wednesday to Wednesday). 5YR based on monthly data

Year-on-Year Performance - Total Return

| Index % (USD) | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|------|------|------|------|------|------|------|------|------|------|
| Russell 1000 Health Care RIC 22.5/45 Capped Index | 25.6 | 7.1 | -2.5 | 22 | 6.7 | 21.2 | 16.8 | 23.3 | -4 | 2.4 |

FEATURES

Objective

Designed for use in the creation of index tracking funds, derivatives and as a performance benchmark.

Investability

A transparent and replicable index construction strategy. Stocks in the underlying universe are screened to ensure that the index is tradable.

Capping

Constituents are capped quarterly so that no more than 22.5% of the index weight may be allocated to a single constituent and the sum of the weights of all constituents representing more than 4.5% of the index should not exceed 45% of the total index weight.

Transparency

The index uses a transparent, rules-based construction process. Index methodologies are freely available on the FTSE Russell website.

Industry Classification Benchmark (ICB)

ICB is a comprehensive and rules based, transparent classification methodology based on research and market trends designed to support investment solutions. It was launched in 2005 and enhanced in 2019 with the integration of the Russell Global Sectors (RGS) classification scheme and additional structural enhancements.

Return/Risk Ratio and Drawdown - Total Return

| Index (USD) | Return/Risk Ratio | | | | Drawdown (%) | | | |
|---|-------------------|-----|-----|------|--------------|-------|-------|-------|
| | 1YR | 3YR | 5YR | 10YR | 1YR | 3YR | 5YR | 10YR |
| Russell 1000 Health Care RIC 22.5/45 Capped Index | 1.2 | 0.3 | 0.8 | 0.8 | -9.4 | -16.6 | -28.3 | -28.3 |

Return/Risk Ratio – based on compound annual returns and volatility in Performance and Volatility table
 Drawdown - based on daily data

Top 10 Constituents

| Constituent | ICB Subsector | Net MCap (USDm) | Wgt % |
|--------------------------|---------------------------------|------------------|--------------|
| Lilly (Eli) & Co | Pharmaceuticals | 683,181 | 12.03 |
| Unitedhealth Group | Health Care Management Services | 529,116 | 9.32 |
| Johnson & Johnson | Pharmaceuticals | 380,242 | 6.70 |
| AbbVie Inc | Pharmaceuticals | 327,865 | 5.77 |
| Merck & Co | Pharmaceuticals | 286,457 | 5.05 |
| Thermo Fisher Scientific | Medical Equipment | 233,887 | 4.12 |
| Danaher Corp | Medical Equipment | 183,160 | 3.23 |
| Abbott Laboratories | Medical Equipment | 182,979 | 3.22 |
| Amgen Corp | Pharmaceuticals | 178,040 | 3.14 |
| Pfizer | Pharmaceuticals | 172,901 | 3.05 |
| Totals | | 3,157,828 | 55.62 |

Index Characteristics

| Attributes | Russell 1000 Health Care RIC 22.5/45 Capped |
|-------------------------|---|
| Number of constituents | 107 |
| Dividend Yield % | 1.52 |
| Constituent (Wgt %) | |
| Average | 0.93 |
| Largest | 12.03 |
| Median | 0.25 |
| Top 10 Holdings (Wgt %) | 55.62 |

INFORMATION

Index Universe

Russell 1000

Index Launch

9 July 2021

Base Date

19 March 2021

Base Value

1000

Investability Screen

Actual free float and liquidity screen applied to underlying indexes

Index Calculation

Real-time and end-of-day

End-of-Day Distribution

Via SFTP and email

Currency

USD, EUR, GBP, JPY, AUD, CNY, HKD, CAD

Review Dates

Annually in June with Share and IPO updates in March, September and December.

Bloomberg Tickers

EOD Price Return - RIYHCPR
 EOD Total Return - RIYHCTR
 Real-time Total Return - RIYHC1

RIC Codes

EOD Price Return - .FRRIYHCU
 EOD Total Return - .TFRRIYHCU

© 2024 London Stock Exchange Group plc and its applicable group undertakings ("LSEG"). LSEG includes (1) FTSE International Limited ("FTSE"), (2) Frank Russell Company ("Russell"), (3) FTSE Global Debt Capital Markets Inc. and FTSE Global Debt Capital Markets Limited (together, "FTSE Canada"), (4) FTSE Fixed Income Europe Limited ("FTSE FI Europe"), (5) FTSE Fixed Income LLC ("FTSE FI"), (6) FTSE (Beijing) Consulting Limited ("WOFE") (7) Refinitiv Benchmark Services (UK) Limited ("RBSL"), (8) Refinitiv Limited ("RL") and (9) Beyond Ratings S.A.S. ("BR"). All rights reserved.

FTSE Russell® is a trading name of FTSE, Russell, FTSE Canada, FTSE FI, FTSE FI Europe, WOFE, RBSL, RL, and BR. "FTSE®", "Russell®", "FTSE Russell®", "FTSE4Good®", "ICB®", "Refinitiv", "Beyond Ratings®", "WMR™", "FR™" and all other trademarks and service marks used herein (whether registered or unregistered) are trademarks and/or service marks owned or licensed by the applicable member of LSEG or their respective licensors and are owned, or used under licence, by FTSE, Russell, FTSE Canada, FTSE FI, FTSE FI Europe, WOFE, RBSL, RL or BR. FTSE International Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator. Refinitiv Benchmark Services (UK) Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator.

All information is provided for information purposes only. All information and data contained in this publication is obtained by LSEG, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical inaccuracy as well as other factors, however, such information and data is provided "as is" without warranty of any kind. No member of LSEG nor their respective directors, officers, employees, partners or licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the accuracy, timeliness, completeness, merchantability of any information or LSEG Products, or of results to be obtained from the use of LSEG products, including but not limited to indices, rates, data and analytics, or the fitness or suitability of the LSEG products for any particular purpose to which they might be put. The user of the information assumes the entire risk of any use it may make or permit to be made of the information.

No responsibility or liability can be accepted by any member of LSEG nor their respective directors, officers, employees, partners or licensors for (a) any loss or damage in whole or in part caused by, resulting from, or relating to any inaccuracy (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analysing, editing, transcribing, transmitting, communicating or delivering any such information or data or from use of this document or links to this document or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if any member of LSEG is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, such information.

No member of LSEG nor their respective directors, officers, employees, partners or licensors provide investment advice and nothing in this document should be taken as constituting financial or investment advice. No member of LSEG nor their respective directors, officers, employees, partners or licensors make any representation regarding the advisability of investing in any asset or whether such investment creates any legal or compliance risks for the investor. A decision to invest in any such asset should not be made in reliance on any information herein. Indices and rates cannot be invested in directly. Inclusion of an asset in an index or rate is not a recommendation to buy, sell or hold that asset nor confirmation that any particular investor may lawfully buy, sell or hold the asset or an index or rate containing the asset. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.

Past performance is no guarantee of future results. Charts and graphs are provided for illustrative purposes only. Index and/or rate returns shown may not represent the results of the actual trading of investable assets. Certain returns shown may reflect back-tested performance. All performance presented prior to the index or rate inception date is back-tested performance. Back-tested performance is not actual performance, but is hypothetical. The back-test calculations are based on the same methodology that was in effect when the index or rate was officially launched. However, back-tested data may reflect the application of the index or rate methodology with the benefit of hindsight, and the historic calculations of an index or rate may change from month to month based on revisions to the underlying economic data used in the calculation of the index or rate.

No part of this information may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the applicable member of LSEG. Use and distribution of LSEG data requires a licence from LSEG and/or its licensors.

Data definitions available from
info@ftserussell.com

To learn more, visit lseg.com/ftse-russell;
email info@ftserussell.com; or
call your regional Client Services Team office:

EMEA

+44 (0) 20 7866 1810

North America

+1 877 503 6437

Asia-Pacific

Hong Kong +852 2164 3333

Tokyo +81 3 6441 1430

Sydney +61 (0) 2 7228 5659